Chugai says Roche Phase III trials show vamikibart sustains vision gains through 52 weeks in uveitic macular edema

(AWP Alliance News) - Chugai Pharmaceutical reported that Roche released one-year Phase III results for vamikibart in uveitic macular edema, with the data already presented at the American Academy of Ophthalmology 2026 Annual Meeting. The studies showed sustained improvements in vision with reductions in macular swelling through 52 weeks.

About two-thirds of patients who moved to as-needed dosing did not require additional treatment, while most of those who did needed only one more injection. The drug's safety profile remained consistent over the one-year period.

https://docs.publicnow.com/301B43A4DB9D68EC9101E2C0B5FBCA7F5FEFB11B

Disclaimer: This news brief was created using generative artificial intelligence. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.